Fourth quarter (2023-06-01 until 2023-08-31)
● Operating Income amounted to 3,947 (1,405) TSEK.
● Net Income for Cellaviva amounted to 2,758 (1,359) TSEK.
● Operating result amounted to -8,640 (-8,563) TSEK.
● Earnings per share* amounted to -0.25 (-0.25) SEK .
● Cash and bank amounted to 50,025 (97,117) TSEK.
● Solidity** amounted to 85.3 (92.7)
Twelve months (2022-09-01 till 2023-08-31)
● Operating income amounted to 13,955 (6,229) TSEK.
● Net Income for Cellaviva amounted to 10,113 (5,589) TSEK.
● Operating result amounted to -39,812 (-34,554) TSEK.
● Earnings per share* amounted to -1.16 (-1.01) SEK .
● The Board of Directors proposes that no dividend shall be paid for the financial year.
Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the fourth quarter 2022/2023: 34,379,523 (34,379,523) shares. Average number of shares for the full year 2022/2023: 34,379,523 (30,411,847) shares. Number of shares in NextCell as of August 31, 2023: 34,379,523 (34,379,523) shares.
**Solidity: Equity to total balance sheet.
Significant events in the fourth quarter
● NextCell announced at the beginning of July that the clinical trial ProTrans 19+SE would start recruiting patients in the high dose group, which is the last dose group. Three patients treated with medium dose of ProTrans have been clinically evaluated and the data has been reviewed by the Data Safety Monitoring Board, which now allows continued treatment with high dose ProTrans for severe pneumonia caused by COVID-19, Influenza, Human metapneumovirus (HMPV), and respiratory syncytial virus (RSV).
Significant events after the reporting period
●
This disclosure contains information that
For more information about
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com
Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma
For more information about Cellaviva, please contact
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se
Instagram: https://www,instagram.com/cellaviva
Certified Adviser
About
NextCell is a cell therapy company in phase II trials with the drug candidate
https://news.cision.com/nextcell-pharma-ab/r/nextcell-publishes-its-year-end-report-2022-2023,c3861708
https://mb.cision.com/Main/15834/3861708/2385485.pdf
https://mb.cision.com/Public/15834/3861708/8d3ea5a6886e966d.pdf
(c) 2023 Cision. All rights reserved., source